ES2426599T3 - Formulación oral anticáncer - Google Patents

Formulación oral anticáncer Download PDF

Info

Publication number
ES2426599T3
ES2426599T3 ES09795224T ES09795224T ES2426599T3 ES 2426599 T3 ES2426599 T3 ES 2426599T3 ES 09795224 T ES09795224 T ES 09795224T ES 09795224 T ES09795224 T ES 09795224T ES 2426599 T3 ES2426599 T3 ES 2426599T3
Authority
ES
Spain
Prior art keywords
formulation
weight
transcutol
tpgs
peg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES09795224T
Other languages
English (en)
Spanish (es)
Inventor
Tengkuang Yeh
Chiung-Tong Chen
Yu-Sheng Chao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
National Health Research Institutes
Original Assignee
National Health Research Institutes
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by National Health Research Institutes filed Critical National Health Research Institutes
Application granted granted Critical
Publication of ES2426599T3 publication Critical patent/ES2426599T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
ES09795224T 2008-07-11 2009-07-10 Formulación oral anticáncer Active ES2426599T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12/171,515 US8026271B2 (en) 2008-07-11 2008-07-11 Formulations of indol-3-yl-2-oxoacetamide compounds
US171515 2008-07-11
PCT/US2009/050210 WO2010006234A2 (en) 2008-07-11 2009-07-10 Anticancer oral formulation

Publications (1)

Publication Number Publication Date
ES2426599T3 true ES2426599T3 (es) 2013-10-24

Family

ID=41505721

Family Applications (1)

Application Number Title Priority Date Filing Date
ES09795224T Active ES2426599T3 (es) 2008-07-11 2009-07-10 Formulación oral anticáncer

Country Status (8)

Country Link
US (1) US8026271B2 (cg-RX-API-DMAC7.html)
EP (1) EP2310363B1 (cg-RX-API-DMAC7.html)
JP (1) JP5596680B2 (cg-RX-API-DMAC7.html)
KR (1) KR101627382B1 (cg-RX-API-DMAC7.html)
CN (1) CN102159541B (cg-RX-API-DMAC7.html)
ES (1) ES2426599T3 (cg-RX-API-DMAC7.html)
TW (1) TWI384984B (cg-RX-API-DMAC7.html)
WO (1) WO2010006234A2 (cg-RX-API-DMAC7.html)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8026271B2 (en) * 2008-07-11 2011-09-27 National Health Research Institutes Formulations of indol-3-yl-2-oxoacetamide compounds
TW201602113A (zh) 2009-06-29 2016-01-16 英塞特公司 作為ｐｉ３ｋ抑制劑之嘧啶酮
WO2011075630A1 (en) * 2009-12-18 2011-06-23 Incyte Corporation Substituted fused aryl and heteroaryl derivatives as pi3k inhibitors
US8759359B2 (en) 2009-12-18 2014-06-24 Incyte Corporation Substituted heteroaryl fused derivatives as PI3K inhibitors
WO2011130342A1 (en) 2010-04-14 2011-10-20 Incyte Corporation FUSED DERIVATIVES AS ΡI3Κδ INHIBITORS
US9062055B2 (en) 2010-06-21 2015-06-23 Incyte Corporation Fused pyrrole derivatives as PI3K inhibitors
CA2822070C (en) 2010-12-20 2019-09-17 Incyte Corporation N-(1-(substituted-phenyl)ethyl)-9h-purin-6-amines as pi3k inhibitors
US9108984B2 (en) 2011-03-14 2015-08-18 Incyte Corporation Substituted diamino-pyrimidine and diamino-pyridine derivatives as PI3K inhibitors
US9126948B2 (en) 2011-03-25 2015-09-08 Incyte Holdings Corporation Pyrimidine-4,6-diamine derivatives as PI3K inhibitors
HRP20190867T1 (hr) 2011-05-12 2019-07-12 Proteostasis Therapeutics, Inc. Regulatori proteostaze
SG10201912484RA (en) 2011-09-02 2020-02-27 Incyte Corp Heterocyclylamines as pi3k inhibitors
AR090548A1 (es) 2012-04-02 2014-11-19 Incyte Corp Azaheterociclobencilaminas biciclicas como inhibidores de pi3k
WO2015073528A1 (en) 2013-11-12 2015-05-21 Proteostasis Therapeutics, Inc. Proteasome activity enhancing compounds
US10077277B2 (en) 2014-06-11 2018-09-18 Incyte Corporation Bicyclic heteroarylaminoalkyl phenyl derivatives as PI3K inhibitors
EP4183789A1 (en) 2015-02-27 2023-05-24 Incyte Holdings Corporation Salts of pi3k inhibitor and processes for their preparation
US9988401B2 (en) 2015-05-11 2018-06-05 Incyte Corporation Crystalline forms of a PI3K inhibitor
WO2016183060A1 (en) 2015-05-11 2016-11-17 Incyte Corporation Process for the synthesis of a phosphoinositide 3-kinase inhibitor
CN119258070A (zh) 2018-06-01 2025-01-07 因赛特公司 治疗pi3k相关病症的给药方案

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6979456B1 (en) * 1998-04-01 2005-12-27 Jagotec Ag Anticancer compositions
US6372251B2 (en) 1999-06-11 2002-04-16 Abbott Laboratories Formulations comprising lipid-regulating agents
US20040092428A1 (en) * 2001-11-27 2004-05-13 Hongming Chen Oral pharmaceuticals formulation comprising paclitaxel, derivatives and methods of administration thereof
TWI323658B (en) * 2001-12-06 2010-04-21 Nat Health Research Institutes Novel compounds of indol-3-yl-2-oxyacetylamide derivatives, pharmaceutical composition thereof, and method for manufacturing the same
BRPI0518484A2 (pt) * 2004-11-24 2008-11-18 Merck & Co Inc composiÇço, cÁpsula, e, processo para preparar a mesma
US20060134204A1 (en) * 2004-12-21 2006-06-22 Wong Patrick S Complexes made using low solubility drugs
TWI376239B (en) * 2006-02-01 2012-11-11 Andrew Xian Chen Vitamin e succinate stabilized pharmaceutical compositions, methods for the preparation and the use thereof
CA2669815A1 (en) * 2006-11-28 2008-06-05 Marinus Pharmaceuticals Nanoparticulate formulations and methods for the making and use thereof
EP2476461A3 (en) * 2007-01-16 2012-10-24 BiPar Sciences, Inc. Formulations For Cancer Treatment
US8026271B2 (en) 2008-07-11 2011-09-27 National Health Research Institutes Formulations of indol-3-yl-2-oxoacetamide compounds

Also Published As

Publication number Publication date
US8026271B2 (en) 2011-09-27
WO2010006234A2 (en) 2010-01-14
EP2310363A4 (en) 2012-03-28
EP2310363B1 (en) 2013-06-05
JP2011527704A (ja) 2011-11-04
US20100010059A1 (en) 2010-01-14
JP5596680B2 (ja) 2014-09-24
CN102159541A (zh) 2011-08-17
EP2310363A2 (en) 2011-04-20
KR101627382B1 (ko) 2016-06-03
KR20110038135A (ko) 2011-04-13
TWI384984B (zh) 2013-02-11
TW201002319A (en) 2010-01-16
CN102159541B (zh) 2014-06-04
WO2010006234A3 (en) 2010-04-08

Similar Documents

Publication Publication Date Title
ES2426599T3 (es) Formulación oral anticáncer
AU2017289038B2 (en) Immunomodulator compounds
JP7673041B2 (ja) 治療薬としての細胞毒素のペプチドコンジュゲート
TW202513571A (zh) 吡啶并[4,3-d]嘧啶化合物
ES2313016T3 (es) Sal de isetionato de un inhibidor selectivo de cdk4.
JP2022028904A (ja) シリコン系薬物複合体及びその使用方法
BR112016017261B1 (pt) Composto, composição farmacêutica, uso de um composto e processo para a fabricação de um composto
BR112021008232A2 (pt) conjugados citostáticos inovadores com ligantes de integrina
TW201938540A (zh) 治療涉及酸性或缺氧性患病組織之疾病之化合物、組合物及方法
CN102665685A (zh) 纯的peg-脂质缀合物
TW200813065A (en) Conjugates of aziridinyl-epothilone analogs and pharmaceutical compositions comprising same
ES3028360T3 (en) Deuterated n-benzenesulfonylbenzamide compound for inhibiting bcl-2 protein and composition and use thereof
WO2018086446A1 (zh) 具有穿过血脑屏障能力的取代的喹唑啉化合物
ES2981015T3 (es) Forma cristalina de compuesto que suprime la actividad de la proteína quinasa y aplicación de la misma
CN101454309B (zh) 焦谷氨酸衍生物的合成和用途
ES2906048T3 (es) Nuevas formas de sal cristalinas de 3-(1,2,4-triazolo[4,3-a]piridin-3-iletinil)-4-metil-N-(4-((4-metilpiperazin-1-il)metil)-3-trifluorometilfenil)benzamida para aplicación médica
WO2017024953A9 (zh) 尼莫地平水溶性衍生物及其制备方法和应用
CN113439084B (zh) 倍癌霉素类似物
CN116003810A (zh) 一类载药的大分子及其制备方法
WO2017156959A1 (zh) 一种小分子肺靶向药物
WO2021172359A1 (ja) Ｃｄｋ９阻害剤プロドラッグ及びそれを内封するリポソーム
HK1158184A (en) Anticancer oral formulation
ES2656699T3 (es) Formas polimorfas de maleato de Icotinib y utilizaciones de las mismas
TW202120511A (zh) 雜環化合物